Edition:
United States

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.84USD
17 Nov 2017
Change (% chg)

$-0.01 (-0.35%)
Prev Close
$2.85
Open
$2.83
Day's High
$2.86
Day's Low
$2.79
Volume
221,043
Avg. Vol
458,347
52-wk High
$3.55
52-wk Low
$1.93

Chart for

About

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating... (more)

Overall

Beta: 0.54
Market Cap(Mil.): $438.32
Shares Outstanding(Mil.): 154.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-PDL Biopharma Inc files for non-timely 10-Q

* PDL Biopharma Inc files for non-timely 10-Q - SEC filing‍​ Source text: (http://bit.ly/2AC3Kyu) Further company coverage:

Nov 13 2017

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

Nov 08 2017

BRIEF-PDL Biopharma Inc reports Q3 revenue $62.7 million

* PDL Biopharma Inc announces third quarter 2017 financial results

Nov 02 2017

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.

Oct 31 2017

CORRECTED-Neos Therapeutics to consider other offers after PDL snub -sources

Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.

Oct 31 2017

BRIEF-PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal

* PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal

Oct 30 2017

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

Oct 30 2017

BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma

* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​

Oct 26 2017

BRIEF-PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share

* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash

Oct 26 2017

BRIEF-PDL Biopharma announces new $25 mln share repurchase program

* PDL Biopharma announces new $25 million share repurchase program Source text for Eikon: Further company coverage:

Sep 25 2017

Earnings vs. Estimates